Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
Date: April 6, 2020
Issue #:
1595Summary:
The FDA has approved two new drugs for sickle cell
disease: crizanlizumab-tmca (Adakveo– Novartis), an
IV P-selectin blocker, and voxelotor (Oxbryta– GBT),
an oral hemoglobin S (HbS) polymerization inhibitor.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Adakveo crizanlizumab Droxia Endari Hydrea Hydroxyurea L-glutamine Oxbryta sickle cell disease Siklos voxelotor Source Type: research
More News: Drugs & Pharmacology | Sickle Cell Anemia